UK markets closed

GenSight Biologics S.A. (0RIM.L)

LSE - LSE Delayed price. Currency in EUR
Add to watchlist
0.4080+0.0065 (+1.62%)
At close: 08:00AM BST

GenSight Biologics S.A.

74, rue du Faubourg Saint-Antoine
Paris 75012
France
33 1 76 21 72 20
https://www.gensight-biologics.com

Sector(s)
Industry
Full-time employees16

Key executives

NameTitlePayExercisedYear born
Ms. Laurence RodriguezCEO & DirectorN/AN/A1968
Dr. Jose-Alain Sahel M.D., Ph.D.Scientific Founder, Vice Chairman of Scientific Advisory Board & Board ObserverN/AN/AN/A
Prof. Botond Roska M.D., Ph.D.Scientific Founder & Chairman of Scientific Advisory BoardN/AN/AN/A
Dr. Luk H. Vandenberghe M.D., Ph.D.Scientific Founder & Member of Scientific Advisory BoardN/AN/AN/A
Dr. Serge Picaud Ph.D.Scientific Founder & Member of Scientific Advisory BoardN/AN/AN/A
Dr. Constance L. Cepko Ph.D.Scientific Founder & Member of Scientific Advisory BoardN/AN/AN/A
Mr. Ivan TortetInterim Chief Financial OfficerN/AN/A1966
Mr. Scott JeffersChief Technical OfficerN/AN/AN/A
Dr. Barrett Katz CMO, M.B.A., M.D.ConsultantN/AN/A1951
Dr. Magali Taiël M.D.Chief Medical OfficerN/AN/AN/A
Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

GenSight Biologics S.A., a clinical-stage biotechnology company, discovers, develops, and commercializes therapies for mitochondrial and neurodegenerative retinal diseases of the eye and central nervous system. The company develops its products through gene therapy-based mitochondrial targeting sequence and optogenetics technology platforms. Its lead product candidates include LUMEVOQ (GS010), a recombinant AAV2-based gene therapy, which is in Phase III clinical trials for the treatment of leber hereditary optic neuropathy caused by a mutated ND4 gene; and GS030, which is in Phase I/II clinical trial for the treatment of retinitis pigmentosa, as well as in preclinical stage to treat dry age-related macular degeneration. The company is also developing products that are in preclinical stage targeting ophthalmic and neurodegenerative diseases. It has license agreements with Sorbonne Université, CNRS, Inserm and SATT Lutech; Inserm Transfert S.A, Genethon, and Harvard; Massachusetts Institute of Technology; Novartis Pharma AG; Sorbonne University, Centre National de la Recherche Scientifique, Institut National de la Santé et de la Recherche Médicale and Satt Lutech; Association Française contre les Myopathies, Inserm Transfert S.A; and non-exclusive license agreement with Adverum Biotechnologies. The company was incorporated in 2012 and is headquartered in Paris, France.

Corporate governance

GenSight Biologics S.A.’s ISS governance QualityScore as of 1 May 2024 is 10. The pillar scores are Audit: 10; Board: 10; Shareholder rights: 4; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.